Galectin-3 as a new negative checkpoint of the immune response is the key target for effective immun...
Galectin-3 as a new negative checkpoint of the immune response is the key target for effective immunotherapy against prostate cancer
About this item
Full title
Author / Creator
Publisher
Cold Spring Harbor: Cold Spring Harbor Laboratory Press
Journal title
Language
English
Formats
Publication information
Publisher
Cold Spring Harbor: Cold Spring Harbor Laboratory Press
Subjects
More information
Scope and Contents
Contents
Prostate cancer (PCa) is a major health problem worldwide. Taxol derivatives-based chemotherapies or immunotherapies are usually proposed depending on the symptomatic status. In the case of immunotherapy, tumors develop robust immune escape mechanisms that abolish any protective response. However, Docetaxel has been shown to enhance the effectivene...
Alternative Titles
Full title
Galectin-3 as a new negative checkpoint of the immune response is the key target for effective immunotherapy against prostate cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2288304280
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2288304280
Other Identifiers
E-ISSN
2692-8205
DOI
10.1101/763409
How to access this item
https://www.proquest.com/docview/2288304280?pq-origsite=primo&accountid=13902
